A number of new medicines have been added to the PBS. The majority of these additions will come into effect on 1 December 2012. The new medicines include:
- Aflibercept (Eylea®) – for the treatment of age-related macular degeneration
- Aprepitant (Emend®) – for the treatment of nausea and vomiting associated with chemotherapy for cancer
- Atenolol (Atenolol-AFT®) – for the treatment of high blood pressure
- Ezetimibe with simvastatin (Vytorin®) – for the treatment of high cholesterol
- Mycophenolate sodium (Myfortic®) – for the treatment of kidney inflammation caused by lupus
- Naloxone hydrochloride (Naloxone Min-I-Jet®) – for the emergency treatment of opioid overdose
- Paraffin compound eye ointment (VitA-POS®) – for the treatment of severe dry eye syndrome
- Rivaroxaban (Xarelto®) – for the treatment of deep vein thrombosis (blood clots)
- Sodium hyaluronate (Hylo®–Fresh) (Hylo®–Forte) – for the treatment of severe dry eye syndrome
- Temozolomide (Temodal®) – for the treatment of certain types of malignant brain cancer.
Some medicines will also increase in price, in order to keep as many medicines as possible on the PBS list. To see a full list of new medicines, and to get a full list of PBS medicine prices, visit the PBS website.